These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes. Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028 [TBL] [Abstract][Full Text] [Related]
27. Maltol-derived ruthenium-cymene complexes with tumor inhibiting properties: the impact of ligand-metal bond stability on anticancer activity in vitro. Kandioller W; Hartinger CG; Nazarov AA; Bartel C; Skocic M; Jakupec MA; Arion VB; Keppler BK Chemistry; 2009 Nov; 15(45):12283-91. PubMed ID: 19821465 [TBL] [Abstract][Full Text] [Related]
28. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes. Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015 [TBL] [Abstract][Full Text] [Related]
29. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes. Hu W; Luo Q; Ma X; Wu K; Liu J; Chen Y; Xiong S; Wang J; Sadler PJ; Wang F Chemistry; 2009 Jul; 15(27):6586-94. PubMed ID: 19533706 [TBL] [Abstract][Full Text] [Related]
30. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands. Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622 [TBL] [Abstract][Full Text] [Related]
31. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate. Wang F; Xu J; Habtemariam A; Bella J; Sadler PJ J Am Chem Soc; 2005 Dec; 127(50):17734-43. PubMed ID: 16351102 [TBL] [Abstract][Full Text] [Related]
32. DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media. Kostrhunova H; Florian J; Novakova O; Peacock AF; Sadler PJ; Brabec V J Med Chem; 2008 Jun; 51(12):3635-43. PubMed ID: 18494458 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and intramolecular and interionic structural characterization of half-sandwich (arene)ruthenium(II) derivatives of bis(pyrazolyl)alkanes. Marchetti F; Pettinari C; Pettinari R; Cerquetella A; Di Nicola C; Macchioni A; Zuccaccia D; Monari M; Piccinelli F Inorg Chem; 2008 Dec; 47(24):11593-603. PubMed ID: 18998632 [TBL] [Abstract][Full Text] [Related]
34. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands. Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401 [TBL] [Abstract][Full Text] [Related]
35. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands. Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875 [TBL] [Abstract][Full Text] [Related]
36. Thiophenolato-bridged dinuclear arene ruthenium complexes: a new family of highly cytotoxic anticancer agents. Gras M; Therrien B; Süss-Fink G; Zava O; Dyson PJ Dalton Trans; 2010 Nov; 39(42):10305-13. PubMed ID: 20890536 [TBL] [Abstract][Full Text] [Related]
37. A novel ruthenium(II) arene based intercalator with potent anticancer activity. Ruiz J; Vicente C; de Haro C; Bautista D Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164 [TBL] [Abstract][Full Text] [Related]
38. Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter? Hanif M; Henke H; Meier SM; Martic S; Labib M; Kandioller W; Jakupec MA; Arion VB; Kraatz HB; Keppler BK; Hartinger CG Inorg Chem; 2010 Sep; 49(17):7953-63. PubMed ID: 20704358 [TBL] [Abstract][Full Text] [Related]
39. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. Bergamo A; Masi A; Peacock AF; Habtemariam A; Sadler PJ; Sava G J Inorg Biochem; 2010 Jan; 104(1):79-86. PubMed ID: 19906432 [TBL] [Abstract][Full Text] [Related]
40. Organometallic osmium arene complexes with potent cancer cell cytotoxicity. Fu Y; Habtemariam A; Pizarro AM; van Rijt SH; Healey DJ; Cooper PA; Shnyder SD; Clarkson GJ; Sadler PJ J Med Chem; 2010 Nov; 53(22):8192-6. PubMed ID: 20977192 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]